Search results
Results From The WOW.Com Content Network
Finasteride is sometimes used in hormone replacement therapy for transgender women due to its antiandrogenic effects, in combination with a form of estrogen. However, little clinical research of finasteride use for this purpose has been conducted and evidence of safety or efficacy is limited. [8]
A 2017 population-based, matched-cohort study of 93,197 men aged 66 years and older with BPH found that finasteride and dutasteride were associated with a significantly increased risk of depression (HR Tooltip Hazard ratio, 1.94; 95% CI Tooltip Confidence interval, 1.73–2.16) and self-harm (HR, 1.88; 95% CI, 1.34–2.64) during the first 18 ...
Tamsulosin, sold under the brand names including Flomax and Contiflo, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. [6] [7] [8] The evidence for benefit with a kidney stone is better when the stone is larger. [8] Tamsulosin is taken by mouth. [6]
Finasteride works for most people — that’s hardly in debate. But for those who think it’ll be a miracle for their dormant or dead hair follicles, we’ve got a reality check to share with you.
Tamsulosin: Flomax A blocker that has slight selectivity for α 1 receptors. [2] Relaxation of prostatic smooth muscle. [2] Benign prostatic hyperplasia [2] [11] Orthostatic hypotension [2] Yohimbine: Yocon Blocks α 2 receptor, and increases norepinephrine release, thus increasing CNS activity. [2] Raises blood pressure and heart rate. [2 ...
A review published in the journal Clinical Interventions in Aging, which featured data from three studies comparing dutasteride and finasteride as treatments for male pattern baldness, came to a ...
Research shows that 1mg doses of finasteride are unlikely to cause side effects and there’s no clear evidence that finasteride — both 1mg and 5mg daily doses — negatively affects erectile ...
[37] [50] In fact, the incidence of diarrhea did not differ between the bicalutamide and placebo groups (6.3% vs. 6.4%, respectively) in the Early Prostate Cancer (EPC) clinical trial programme, [51] whereas diarrhea occurs in up to 20% of patients treated with flutamide.